A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease
Crossref DOI link:
Published Online: 2017-11-02
Published Print: 2017-12
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Pudi, Krishna K.
Barnes, Chris N.
Moran, Edmund J.
Funding for this research was provided by: